Catalyst Pharmaceuticals, Inc.
—- Market cap
- —
- Debt
- +$145.25M
- Cash
- −$709.17M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $6.27B · View financials
Decision snapshot: CPRX stock price vs ST: inconclusive — current versus $344.72 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ST's multiple
Implied fair value · at CPRX's multiple
Needs CPRX P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CPRX FY 2025 (ended Dec 31, 2025) · ST FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 69% equity / 31% debt · EV / Revenue 2.31x · EV / EBITDA 15.92x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
CATALYST PHARMACEUTICALS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Sensata Technologies Holding plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.15x
1.02x
Net debt / EBITDA
Leverage against operating earnings
-1.75x
4.24x
Cash and equivalents
Liquid reserves on the balance sheet
$709.17M
$573.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
CPRX vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
CPRX vs SUPN
PERRIGO Co plc
CPRX vs PRGO
Harmony Biosciences Holdings, Inc.
CPRX vs HRMY
HONEYWELL INTERNATIONAL INC
CPRX vs HON
EMERSON ELECTRIC CO
CPRX vs EMR
TE Connectivity plc
CPRX vs TEL
AMPHENOL CORP /DE/
CPRX vs APH
AMETEK INC/
CPRX vs AME
Fortive Corp
CPRX vs FTV
$145.25M
$2.85B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.